A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA–NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA–NC by intramuscular route.

• Publication year

  2008

• Venue

  Vaccine

• Publication date

  2008-09-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2008.09.006PMID 18805454PMCID 7115531
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two-Way Antigenic Cross-Reactivity between Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Group 1 Animal CoVs Is Mediated through an Antigenic Site in the N-Terminal Region of the SARS-CoV Nucleoprotein

  2007cited by this paper
• Polylactide-Coglycolide Microspheres CoEncapsulating Recombinant Tandem Prion Protein with CpG-Oligonucleotide Break Self-Tolerance to Prion Protein in Wild-Type Mice and Induce CD4 and CD8 T Cell Responses1

  2007cited by this paper
• [Immunisation strategies for the management of severe acute respiratory syndrome (SARS)].

  2007cited by this paper
• Cell Type-Specific Cleavage of Nucleocapsid Protein by Effector Caspases during SARS Coronavirus Infection

  2007cited by this paper
• Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS

  2007cited by this paper
• Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant.

  2006cited by this paper
• Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.

  2006cited by this paper
• Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.

  2006cited by this paper
• Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

  2005cited by this paper
• Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice.

  2005cited by this paper
• Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region

  2005cited by this paper
• The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice

  2005cited by this paper
• Academic Editor: Sherif Zaki, Centers for Disease Control, United States of America

  2005cited by this paper
• Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination

  2005cited by this paper
• Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry

  2004cited by this paper
• Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine

  2004cited by this paper
• Evidence of airborne transmission of the severe acute respiratory syndrome virus.

  2004cited by this paper
• Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine

  2004cited by this paper
• Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol

  2004cited by this paper
• Immunogenicity of SARS inactivated vaccine in BALB/c mice

  2004cited by this paper
• Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.

  2004cited by this paper
• Generation and Characterization of DNA Vaccines Targeting the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus

  2004cited by this paper
• A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

  2004cited by this paper
• Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets

  2004cited by this paper
• [Dynamic changes of plasma cytokine levels in patients with severe acute respiratory syndrome].

  2003cited by this paper
• Transmission Dynamics of the Etiological Agent of SARS in Hong Kong: Impact of Public Health Interventions

  2003cited by this paper
• Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.

  2003cited by this paper
• Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.

  2003cited by this paper
• Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3L

  2003cited by this paper
• SARS: epidemiology

  2003cited by this paper
• Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report

  2003cited by this paper
• Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome.

  2003cited by this paper
• SARS: clinical features and diagnosis

  2003cited by this paper
• Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome.

  2003cited by this paper
• Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus

  2003cited by this paper
• Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

  2003cited by this paper
• Live viral vectors: vaccinia virus.

  2003cited by this paper
• The Mycoplasma‐derived lipopeptide MALP‐2 is a potent mucosal adjuvant

  2002cited by this paper
• Fibronectin‐binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route

  1998cited by this paper
• The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection

  1997cited by this paper
• Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus.

  1995cited by this paper
• Protection of Cats from Infectious Peritonitis by Vaccination with a Recombinant Raccoon Poxvirus Expressing the Nucleocapsid Gene of Feline Infectious Peritonitis Virus

  1995cited by this paper
• Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection.

  1993cited by this paper
• Infectious Agents and Cancer Immunization of Mice with the Nef Gene from Human Immunodeficiency Virus Type 1: Study of Immunological Memory and Long-term Toxicology

  year unknowncited by this paper

• The Combination of TLR4 and TLR9 Agonists with Self-Amplifying RNA Lipid Nanoparticles Leads to a More Powerful Immune Response Against SARS-CoV-2

  2025cites this paper
• Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

  2023cites this paper
• Genomic characterization and molecular evolution of SARS-CoV-2 in Rio Grande do Sul State, Brazil

  2023cites this paper
• Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence

  2022cites this paper
• Design and application of nanoparticles as vaccine adjuvants against human corona virus infection

  2021cites this paper
• Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine

  2021cites this paper
• Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?

  2020cites this paper
• Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population

  2020cites this paper
• Standpoints on immune responses against COVID-19

  2020cites this paper
• Global dynamics of a novel deterministic and stochastic SIR epidemic model with vertical transmission and media coverage

  2020cites this paper
• Novel Approaches to Fight Prion Diseases

  2020cites this paper
• Vaccine design based on 16 epitopes of SARS‐CoV‐2 spike protein

  2020cites this paper
• Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population.

  2020cites this paper
• Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver

  2017cites this paper
• A stochastic SIS epidemic model with vaccination

  2017cites this paper
• University of Groningen Development of adjuvanted influenza vaccines for pulmonary delivery

  2017cites this paper
• Comparison of homologous and heterologous prime-boost immunizations combining MVA-vectored and plant-derived VP2 as a strategy against IBDV.

  2017cites this paper
• The Evolution of Poxvirus Vaccines

  2015cites this paper
• Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein

  2015cites this paper
• Modified vaccinia virus Ankara as vaccine vectors in human and veterinary medicine

  2014cites this paper
• Use of S-[2,3-Bispalmitoyiloxy-(2R)-Propyl]-R-Cysteinyl-Amido-Monomethoxy Polyethylene Glycol as an Adjuvant Improved Protective Immunity Associated with a DNA Vaccine Encoding Cu,Zn Superoxide Dismutase of Brucella abortus in Mice

  2014cites this paper
• Characterization of recombinant Modified Vaccinia virus Ankara for delivery of Middle East Respiratory Syndrome Coronavirus spike protein antigens

  2014cites this paper
• Vaccine adjuvants: key tools for innovative vaccine design.

  2013cites this paper
• Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies

  2013cites this paper
• Improvement of influenza vaccines by using a saponin-derived adjuvant

  2013cites this paper
• Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.

  2012cites this paper
• Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.

  2011cites this paper
• Characterizing the potential of DEC-205-mediated antigen delivery to dendritic cells as a tool to induce adaptive immunity against hepatitis C virus infection

  2011cites this paper
• Natural innate cytokine response to immunomodulators and adjuvants in human precision-cut lung slices.

  2010cites this paper
• Comparative study of synonymous codon usage variations between the nucleocapsid and spike genes of coronavirus, and C-type lectin domain genes of human and mouse

  2009cites this paper
• Publication List 2008

  2009cites this paper